Jeffrey Jones, MD, MPH, began his medical education at the University of Michigan Medical School in Ann Arbor, MI, before completing a residency in internal medicine at McGill University Health Centre in Montreal, Canada, followed by a clinical fellowship in hematology and oncology at the University of Texas in Houston, TX.
Dr Jones gained 11 years’ experience as an Associate Professor of Internal Medicine in the Division of Hematology at Ohio State University in Columbus, OH, and at present is the Vice President of Global Drug Development in Lymphoma and Myeloid at Bristol Myers Squibb.
Speaking on chronic lymphocytic leukemia
Dr Jones’ research interests lie in the development of drugs for the treatment of chronic lymphocytic leukemia (CLL) and he has authored numerous papers investigating CLL therapeutics, such as venetoclax and ibrutinib. Dr Jones is also the Principal Investigator of various Phase I/II clinical trials evaluating monotherapies and combination therapies for patients with various types of leukemia and multiple myeloma. He has presented his research works in the field of CLL at many national and international conferences.